Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Harrison Avenue, Suite 900, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 561 % -45.7%
Debt-to-equity 61.4 % +109%
Return On Equity -62.7 % -7.7%
Return On Assets -38.8 % +13.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.4M shares
Common Stock, Shares, Outstanding 61.4M shares +22.6%
Entity Public Float 234M USD -22.6%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 82M shares +64.6%
Weighted Average Number of Shares Outstanding, Diluted 82M shares +64.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 110M USD +0.76%
General and Administrative Expense 34.1M USD +6.86%
Operating Income (Loss) -129M USD +8.49%
Nonoperating Income (Expense) 9.97M USD +18.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -119M USD +31.5%
Income Tax Expense (Benefit) 384K USD +6.67%
Net Income (Loss) Attributable to Parent -119M USD +10.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 126M USD +113%
Accounts Receivable, after Allowance for Credit Loss, Current 9M USD
Assets, Current 251M USD +37.3%
Property, Plant and Equipment, Net 31.4M USD -10.1%
Operating Lease, Right-of-Use Asset 27.4M USD -6.95%
Other Assets, Noncurrent 159K USD -41.1%
Assets 315M USD +25%
Accounts Payable, Current 3.98M USD -27.7%
Employee-related Liabilities, Current 6.7M USD +9.08%
Liabilities, Current 41.6M USD +84.2%
Operating Lease, Liability, Noncurrent 40.1M USD -7.96%
Liabilities 110M USD +62.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.32M USD -59.6%
Retained Earnings (Accumulated Deficit) -452M USD -35.9%
Stockholders' Equity Attributable to Parent 205M USD +11.3%
Liabilities and Equity 315M USD +25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD -63.1%
Net Cash Provided by (Used in) Financing Activities 246K USD
Net Cash Provided by (Used in) Investing Activities 9.85M USD -51.5%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 61.4M shares +22.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -28.1M USD -817%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 130M USD +105%
Deferred Tax Assets, Valuation Allowance 54.5M USD +64.6%
Deferred Tax Assets, Gross 66.6M USD +43.8%
Operating Lease, Liability 5.4M USD
Depreciation 7.91M USD +45.2%
Payments to Acquire Property, Plant, and Equipment 1.38M USD -84.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -120M USD +8.71%
Property, Plant and Equipment, Gross 49.7M USD +9.6%
Operating Lease, Liability, Current 3.65M USD +26.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 41.9M USD +60.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.48M USD +100%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 6.4M USD
Amortization of Intangible Assets 800K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 6.2M USD
Deferred Tax Assets, Net of Valuation Allowance 12.2M USD -8.16%
Share-based Payment Arrangement, Expense 4.87M USD +22.6%
Operating Leases, Future Minimum Payments, Due in Three Years 6.6M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%